| Literature DB >> 30842676 |
Helai P Mohammad1, Olena Barbash1, Caretha L Creasy2.
Abstract
Epigenetic dysregulation is a common feature of most cancers, often occurring directly through alteration of epigenetic machinery. Over the last several years, a new generation of drugs directed at epigenetic modulators have entered clinical development, and results from these trials are now being disclosed. Unlike first-generation epigenetic therapies, these new agents are selective, and many are targeted to proteins which are mutated or translocated in cancer. This review will provide a summary of the epigenetic modulatory agents currently in clinical development and discuss the opportunities and challenges in their development. As these drugs advance in the clinic, drug discovery has continued with a focus on both novel and existing epigenetic targets. We will provide an overview of these efforts and the strategies being employed.Entities:
Mesh：
Substances：
Year: 2019 PMID： 30842676 DOI： 10.1038/s41591-019-0376-8
Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440